Compass Therapeutics
Clinical trials sponsored by Compass Therapeutics, explained in plain language.
COMPASS Therapeutics is a biopharmaceutical company developing psychedelic-based therapies for mental health.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New experimental drug CTX-8371 enters first human tests for tough cancers Results expected Dec 2026 (estimated)
- New combo therapy shows promise for Tough-to-Treat bile duct cancer Results expected Aug 2027 (estimated) May already have reported ↗ 🚀 Make-or-break
-
New cancer drug CTX-10726 enters first human tests
Disease control Recruiting nowThis early-stage trial tests an experimental drug called CTX-10726 in about 70 people with advanced gastroesophageal, liver, endometrial, or kidney cancers that have stopped responding to standard treatments. The main goal is to check safety and find the right dose. Participants …
Phase 1 • Sponsor: Compass Therapeutics • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New experimental drug CTX-8371 enters first human tests for tough cancers
Disease control Recruiting nowThis early-stage study is testing an experimental drug called CTX-8371 in people with advanced lung, breast, lymphoma, head and neck, or skin cancers that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 85 parti…
Phase 1 • Sponsor: Compass Therapeutics • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC